GlassScriptPhysician profile
Wendy Davis
NPI 1265005110
$11,357.48
in general payments reported to CMS, 2019-2025
40 companies · $2,777 in 2025
The $2,777 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,266 · 2022: $1,943 · 2023: $2,434 · 2024: $2,938 · 2025: $2,777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,108 · Education: $40.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,108.20 |
| Education | $40.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,677.01 | 2021-2025 | |
| Novo Nordisk INC | $878.39 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $769.20 | 2021-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $664.30 | 2021-2025 | Jardiance, Tradjenta |
| Daiichi Sankyo INC. | $624.19 | 2023-2025 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $552.54 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $510.39 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $476.58 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $322.66 | 2021-2024 | |
| Vanda Pharmaceuticals INC. | $269.89 | 2024-2025 | Fanapt |
| Corcept Therapeutics | $226.77 | 2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $208.18 | 2023-2024 | Quviviq |
| Pfizer INC. | $199.55 | 2023-2025 | |
| Medtronic, INC. | $197.63 | 2021-2023 | Minimed 780g, Venaseal |
| Abbott Laboratories | $176.60 | 2024-2025 | Freestyle Libre 3 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $163.47 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Insulet Corporation | $157.18 | 2021-2022 | |
| Amgen INC. | $155.30 | 2021-2024 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $147.55 | 2022 | |
| Astellas Pharma US INC | $130.88 | 2022-2025 | Veozah |
| Regeneron Healthcare Solutions, INC. | $120.89 | 2022 | |
| Tandem Diabetes Care, INC. | $113.91 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mylan Specialty L.P. | $65.53 | 2022-2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $62.71 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.53 | 2025 | Caplyta |
| Soleno Therapeutics, INC. | $52.23 | 2025 | Vykat Xr |
| Lundbeck LLC | $47.39 | 2023-2025 | Vyepti, Rexulti |
| Scilex Pharmaceuticals INC. | $42.12 | 2023 | Ztlido |
| Xeris Pharmaceuticals, INC. | $41.09 | 2023-2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $31.17 | 2021-2022 | |
| Indivior INC. | $28.54 | 2024 | Sublocade |
| Aimmune Therapeutics, INC. | $25.85 | 2025 | Zenpep |
| Phadia US INC. | $25.78 | 2023 | Immunocap |
| Biohaven Pharmaceuticals, INC. | $23.85 | 2021 | |
| Neurocrine Biosciences, INC. | $22.94 | 2024 | Ingrezza |
| Viatris Specialty LLC | $20.51 | 2025 | Yupelri |
| Tanabe Pharma America, INC. | $20.12 | 2024 | |
| Nevro Corp. | $18.11 | 2023 | Senza |
| Takeda Pharmaceuticals U.S.A., INC. | $17.39 | 2022 | |
| Philips North America LLC | $15.56 | 2024 | (Ak6) Vest Therapy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.